Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, ...

Discover key insights from ADC Therapeutics' Q4 2024 earnings call, including ZYNLONTA’s commercial success, clinical trial updates, and strategic ...

We made significant progress in advancing our strategy to expand the use of ZYNLONTA into earlier lines of DLBCL and indolent lymphomas. December included completion of enrollment in our pivotal ...

Reports Q4 revenue $16.4M vs. $16.6M last year. “We achieved several key milestones in 2024, advancing our expansion trials with Zynlonta in ...

SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...

Computed tomography (CT) and 18 F-fluorodeoxyglucose (FDG)-PET are the established imaging modalities for staging and response assessment in malignant lymphoma. Combined FDG-PET/CT has higher ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Research analysts at StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX – Get Free Report) in a research note issued on Friday. The firm set a “hold” rating on the ...